Guobang Pharma Ltd. (SHA:605507)
China
· Delayed Price · Currency is CNY 26.18
-0.48 (-1.80%)
Mar 9, 2026, 3:00 PM CST
Guobang Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Operating Revenue | 5,919 | 5,867 | 5,327 | 5,704 | 4,493 | 4,199 | Upgrade
|
| Other Revenue | 23.85 | 23.85 | 22.35 | 17.33 | 12.43 | 7.07 | Upgrade
|
| Revenue | 5,943 | 5,891 | 5,349 | 5,721 | 4,505 | 4,206 | Upgrade
|
| Revenue Growth (YoY) | 4.00% | 10.12% | -6.49% | 26.98% | 7.11% | 10.63% | Upgrade
|
| Cost of Revenue | 4,461 | 4,455 | 4,141 | 4,190 | 3,212 | 2,799 | Upgrade
|
| Gross Profit | 1,482 | 1,435 | 1,209 | 1,531 | 1,294 | 1,407 | Upgrade
|
| Selling, General & Admin | 341.51 | 345.57 | 365.25 | 339.93 | 297.29 | 241.05 | Upgrade
|
| Research & Development | 208.2 | 215.05 | 190.51 | 197.54 | 155.27 | 137.19 | Upgrade
|
| Other Operating Expenses | 34.98 | 25.81 | 30.96 | 31.9 | 23.67 | 24.54 | Upgrade
|
| Operating Expenses | 590.78 | 598.5 | 579.55 | 581.08 | 478.27 | 402.36 | Upgrade
|
| Operating Income | 890.91 | 836.84 | 629.3 | 949.97 | 815.55 | 1,005 | Upgrade
|
| Interest Expense | -22.7 | -27.28 | -22.58 | -16.55 | -28.72 | -35.52 | Upgrade
|
| Interest & Investment Income | 34.76 | 42.89 | 65 | 48.9 | 22.66 | 16.89 | Upgrade
|
| Currency Exchange Gain (Loss) | 32.46 | 32.46 | 22.04 | 58.72 | -14.48 | -48.39 | Upgrade
|
| Other Non Operating Income (Expenses) | -10.15 | -5.48 | -7.41 | -4.31 | -2.13 | -11.39 | Upgrade
|
| EBT Excluding Unusual Items | 925.28 | 879.43 | 686.35 | 1,037 | 792.88 | 926.2 | Upgrade
|
| Gain (Loss) on Sale of Investments | 11.56 | 14.4 | 10.34 | 4.56 | 6.26 | 0.03 | Upgrade
|
| Gain (Loss) on Sale of Assets | 14.78 | -9.11 | 0.72 | -15.84 | 0.3 | -1.52 | Upgrade
|
| Asset Writedown | 36.82 | -6.54 | -5.8 | -0.05 | -9.31 | -5.31 | Upgrade
|
| Other Unusual Items | 9.78 | 9.78 | 6.04 | 10.24 | 16.65 | 24.03 | Upgrade
|
| Pretax Income | 998.22 | 887.97 | 697.65 | 1,036 | 806.78 | 943.44 | Upgrade
|
| Income Tax Expense | 128.39 | 107.39 | 87.67 | 115.02 | 100.55 | 133.15 | Upgrade
|
| Earnings From Continuing Operations | 869.83 | 780.58 | 609.98 | 920.62 | 706.23 | 810.29 | Upgrade
|
| Minority Interest in Earnings | 3.13 | 1.02 | 2.49 | 0.28 | -0.2 | -0.29 | Upgrade
|
| Net Income | 872.95 | 781.6 | 612.46 | 920.9 | 706.03 | 810 | Upgrade
|
| Net Income to Common | 872.95 | 781.6 | 612.46 | 920.9 | 706.03 | 810 | Upgrade
|
| Net Income Growth | 24.30% | 27.62% | -33.49% | 30.43% | -12.84% | 157.19% | Upgrade
|
| Shares Outstanding (Basic) | 556 | 558 | 557 | 558 | 512 | 474 | Upgrade
|
| Shares Outstanding (Diluted) | 556 | 558 | 557 | 558 | 512 | 474 | Upgrade
|
| Shares Change (YoY) | -0.21% | 0.27% | -0.24% | 9.09% | 8.01% | -0.28% | Upgrade
|
| EPS (Basic) | 1.57 | 1.40 | 1.10 | 1.65 | 1.38 | 1.71 | Upgrade
|
| EPS (Diluted) | 1.57 | 1.40 | 1.10 | 1.65 | 1.38 | 1.71 | Upgrade
|
| EPS Growth | 24.57% | 27.27% | -33.33% | 19.56% | -19.30% | 159.09% | Upgrade
|
| Free Cash Flow | 597.08 | 287.29 | -231.68 | 213.92 | -624.23 | 246.27 | Upgrade
|
| Free Cash Flow Per Share | 1.07 | 0.52 | -0.42 | 0.38 | -1.22 | 0.52 | Upgrade
|
| Dividend Per Share | 0.606 | 0.606 | 0.302 | 0.600 | 0.700 | - | Upgrade
|
| Dividend Growth | 100.92% | 100.92% | -49.74% | -14.29% | - | - | Upgrade
|
| Gross Margin | 24.93% | 24.37% | 22.60% | 26.76% | 28.72% | 33.45% | Upgrade
|
| Operating Margin | 14.99% | 14.21% | 11.76% | 16.61% | 18.10% | 23.88% | Upgrade
|
| Profit Margin | 14.69% | 13.27% | 11.45% | 16.10% | 15.67% | 19.26% | Upgrade
|
| Free Cash Flow Margin | 10.05% | 4.88% | -4.33% | 3.74% | -13.86% | 5.85% | Upgrade
|
| EBITDA | 1,408 | 1,270 | 950.43 | 1,210 | 1,016 | 1,162 | Upgrade
|
| EBITDA Margin | 23.69% | 21.55% | 17.77% | 21.15% | 22.56% | 27.62% | Upgrade
|
| D&A For EBITDA | 516.6 | 432.83 | 321.14 | 260.21 | 200.9 | 157.11 | Upgrade
|
| EBIT | 890.91 | 836.84 | 629.3 | 949.97 | 815.55 | 1,005 | Upgrade
|
| EBIT Margin | 14.99% | 14.21% | 11.76% | 16.61% | 18.10% | 23.88% | Upgrade
|
| Effective Tax Rate | 12.86% | 12.09% | 12.57% | 11.11% | 12.46% | 14.11% | Upgrade
|
| Revenue as Reported | 5,943 | 5,891 | 5,349 | 5,721 | 4,505 | 4,206 | Upgrade
|
| Advertising Expenses | - | 1.94 | 1.52 | 3.42 | 1.2 | 1.08 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.